Intense accumulation of F-18-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong Hoon | - |
dc.contributor.author | Park, Eun Kyung | - |
dc.contributor.author | Kang, Chang Ho | - |
dc.contributor.author | Kim, Chul Hwan | - |
dc.contributor.author | Choe, Jae Gol | - |
dc.contributor.author | Noh, Won | - |
dc.date.accessioned | 2022-01-07T04:40:37Z | - |
dc.date.available | 2022-01-07T04:40:37Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2009-12 | - |
dc.identifier.issn | 0914-7187 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/134683 | - |
dc.description.abstract | Soft tissue sarcomas are a highly heterogeneous group of malignancies that arise from mesenchymal tissues. Grading of soft tissue sarcomas is an important prerequisite for the choice of therapy and estimation of prognosis. However, incisional biopsy of huge soft tissue sarcoma lesions frequently fails to provide an accurate diagnosis when there is a benign component, cystic changes and/or necrosis. MRI is helpful in evaluating the extent of the sarcoma lesion, vascularization, invasiveness and integrity of surrounding tissue, but definitive differentiation of benignity and malignancy is not possible with it. In this study, positron emission tomography using [F-18]-2-fluoro-2-deoxy-d-glucose successfully guided surgeons to identify the most hypermetabolic and, therefore, the most suitable biopsy sites of huge soft tissue sarcoma. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject | MUSCULOSKELETAL SYSTEM | - |
dc.subject | SARCOMA | - |
dc.subject | PET | - |
dc.subject | MANAGEMENT | - |
dc.subject | HAZARDS | - |
dc.subject | BONE | - |
dc.title | Intense accumulation of F-18-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jong Hoon | - |
dc.contributor.affiliatedAuthor | Park, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Kang, Chang Ho | - |
dc.contributor.affiliatedAuthor | Kim, Chul Hwan | - |
dc.contributor.affiliatedAuthor | Choe, Jae Gol | - |
dc.identifier.doi | 10.1007/s12149-009-0313-x | - |
dc.identifier.scopusid | 2-s2.0-72949101212 | - |
dc.identifier.wosid | 000272564700009 | - |
dc.identifier.bibliographicCitation | ANNALS OF NUCLEAR MEDICINE, v.23, no.10, pp.887 - 889 | - |
dc.relation.isPartOf | ANNALS OF NUCLEAR MEDICINE | - |
dc.citation.title | ANNALS OF NUCLEAR MEDICINE | - |
dc.citation.volume | 23 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 887 | - |
dc.citation.endPage | 889 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | MUSCULOSKELETAL SYSTEM | - |
dc.subject.keywordPlus | SARCOMA | - |
dc.subject.keywordPlus | PET | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | HAZARDS | - |
dc.subject.keywordPlus | BONE | - |
dc.subject.keywordAuthor | Soft tissue tumor | - |
dc.subject.keywordAuthor | Sarcoma | - |
dc.subject.keywordAuthor | FDG PET | - |
dc.subject.keywordAuthor | MR | - |
dc.subject.keywordAuthor | Metabolic biopsy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.